Michael J. Jurczak

Michael J. Jurczak

Auto-generated profile, based on publicly available information

Michael J. Jurczak

Department of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Nature
Verified
Journal Article
Open access
PDF file
JHJorge Henao-Mejia
Jorge Henao-Mejia
Eran ElinavEran Elinav
Eran Elinav
CJChengcheng Jin
Chengcheng Jin
LHLiming Hao
Liming Hao
WMWajahat Z. Mehal
Wajahat Z. Mehal
RFRichard A. Flavell
Richard A. Flavell
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.

21 May 2014 in Nature
Verified
Journal Article
Open access
PDF file
AMAnila K. Madiraju
Anila K. Madiraju
DEDerek M. Erion
Derek M. Erion
YRYasmeen Rahimi
Yasmeen Rahimi
XZXian-Man Zhang
Xian-Man Zhang
DBDemetrios T. Braddock
Demetrios T. Braddock
GSGerald I. Shulman
Gerald I. Shulman
Metformin treatment of rats at physiologically relevant doses inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase. Metformin, possibly the most widely prescribed antidiabetic in the world, specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia. Its molecular mechanism of action remains elusive and is of great interest. This study shows that metformin treatment of rats at physiologically relevant doses inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase (mGPD), which modulates the cytosolic and mitochondrial redox state, resulting in a reduction in endogenous glucose production. These results identify mGPD as one of the molecular targets by which guanides and biguanides inhibit hepatic gluconeogenesis, and provide a novel therapeutic avenue for type 2 diabetes. Metformin is considered to be one of the most effective therapeutics for treating type 2 diabetes because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain or posing a risk of hypoglycaemia1,2. For over half a century, this agent has been prescribed to patients with type 2 diabetes worldwide, yet the underlying mechanism by which metformin inhibits hepatic gluconeogenesis remains unknown. Here we show that metformin non-competitively inhibits the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, resulting in an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis. Acute and chronic low-dose metformin treatment effectively reduced endogenous glucose production, while increasing cytosolic redox and decreasing mitochondrial redox states. Antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rats resulted in a phenotype akin to chronic metformin treatment, and abrogated metformin-mediated increases in cytosolic redox state, decreases in plasma glucose concentrations, and inhibition of endogenous glucose production. These findings were replicated in whole-body mitochondrial glycerophosphate dehydrogenase knockout mice. These results have significant implications for understanding the mechanism of metformin’s blood glucose lowering effects and provide a new therapeutic target for type 2 diabetes.

1 January 2014 in Cell
Verified
Journal Article
Closed access
PCPaul Cohen
Paul Cohen
JLJulia D. Levy
Julia D. Levy
YZYingying Zhang
Yingying Zhang
Andrea FrontiniAndrea Frontini
Andrea Frontini
DKDmitriy P. Kolodin
Dmitriy P. Kolodin
BSBruce M. Spiegelman
Bruce M. Spiegelman

1 February 2015 in Cell
Verified
Journal Article
Closed access
RPRachel J. Perry
Rachel J. Perry
JCJoão-Paulo G. Camporez
João-Paulo G. Camporez
RKRomy Kursawe
Romy Kursawe
PTPaul M. Titchenell
Paul M. Titchenell
DZDongyan Zhang
Dongyan Zhang
GSGerald I. Shulman
Gerald I. Shulman

4 September 2011 in Nature
Verified
Journal Article
Open access
PDF file
JCJang Hyun Choi
Jang Hyun Choi
ABAlex Banks
Alex Banks
TKTheodore M. Kamenecka
Theodore M. Kamenecka
SBScott A. Busby
Scott A. Busby
MCMichael J. Chalmers
Michael J. Chalmers
PGPatrick R. Griffin
Patrick R. Griffin
The nuclear receptor PPARγ is the target of thiazolidinedione antidiabetics including rosiglitazone and pioglitazone. These full PPARγ agonists are effective and well tolerated in most patients, but cause fluid retention and weight gain in a minority. In this proof-of-concept study, Choi et al. show the development of specific PPARγ ligands that retain antidiabetic activity through blockade of Cdk5-mediated PPARγ phosphorylation, but that are not full PPARγ agonists. In mouse models, these ligands do not cause the side effects sometimes associated with full PPARγ agonists. PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone1. These drugs are full classical agonists for this nuclear receptor, but recent data have shown that many PPARγ-based drugs have a separate biochemical activity, blocking the obesity-linked phosphorylation of PPARγ by Cdk5 (ref. 2). Here we describe novel synthetic compounds that have a unique mode of binding to PPARγ, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice. Moreover, one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PPARγ drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ.

1 October 2013 in Cell
Verified
Journal Article
Closed access
WIWilliam J. Israelsen
William J. Israelsen
TDTalya L. Dayton
Talya L. Dayton
SDShawn M. Davidson
Shawn M. Davidson
BFBrian P. Fiske
Brian P. Fiske
AHAaron M. Hosios
Aaron M. Hosios
MHMatthew G. Vander Heiden
Matthew G. Vander Heiden